Ignite Creation Date:
2024-05-06 @ 7:04 PM
Last Modification Date:
2024-10-26 @ 2:59 PM
Study NCT ID:
NCT05880485
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-11-09
First Post:
2023-04-26
Brief Title:
Online Adaptive Radiotherapy Cervical Cancer With Reduced Margin for Cervical Cancer
Sponsor:
Peking Union Medical College Hospital
Organization:
Peking Union Medical College Hospital
Study Overview
Official Title:
A Prospective Study to Evaluate Online Adaptive Radiotherapy in Cervical Cancer With Reduced Margin
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Online adaptive radiotherapy oART has demonstrated to be feasible to reduce planning target volume PTV margins for cervical cancer To explore the value of reduced margins in oART for cervical cancer we conducted a prospective clinical trial to determine the clinical efficacy and toxicity of reduced margins
Detailed Description:
This is an investigator-initiated efficacious single-center open-label clinical trial study This study hypothesizes that the use of reduced PTV margins in oART for cervical cancer could decrease toxicity and achieve more accurate dosimetric coverage A dose of 504 Gy is delivered to clinical target volume CTV with reduced margin oART Patients receive cisplatin based concurrent chemotherapy The primary endpoint is acute toxicity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None